系律师出会听 DE LAW FIRM 免于发出要约事宜法律意见书 山东众成清泰(济南)律师事务所 关于 法律意见书 众成清泰律师事务所 JOINTIDE LAW FIRM 济南市历下区经十路 11111 号华润大厦 55-57 层 邮编：250101 电话/Tel:(+86)0531-66590909 传真/Fax:(+86)0531-66590906 二〇二五年六月 免于发出要约事宜法律意见书 目录 | 释 义 | | --- | | F T | | 一、收购人及其一致行动人的主体资格 | | 二、本次收购是否属于《收购管理办法》规定的可免于发出要约的情形 | | 三、本次收购履行的法定程序 | | 四、本次收购的法律障碍 | | 五、本次收购有关的信息披露 | | 六、收购人在本次收购过程中是否存在证券违法行为 | | 七、结论意见 15 | 免于发出要约事宜法律意见书 济南财投新动能投资管理有限公司及其一致行动人 免于发出要约事宜的 众成清泰律师事务所 - IOINTIDE LAW FIRM 山东众成清泰(济南)律师事务所 关于济南财投新动能投资管理有限公司及其一致行 动人免于发出要约事宜的 法律意见书 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-042 山东科源制药股份有限公司 关于本次重组相关主体买卖股票情况自查报告的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 根据中国证券登记结算有限责任公司出具的《信息披露义务人持股及股份变 更查询证明》和《股东股份变更明细清单》，以及本次交易的相关各方出具的《自 查报告》、相关方出具的声明承诺等文件，本次重组相关主体在自查期间买卖上 市公司股票的行为不构成内幕交易行为，对本次交易不构成实质性障碍。 在本次交易过程中上市公司已经采取了严格的保密措施，尽可能缩小知情人 员范围，但仍无法排除本次交易存在因涉嫌内幕交易导致本次交易被暂停、中止 或取消的风险。提请广大投资者注意相关风险。 山东科源制药股份有限公司（以下简称"科源制药"、"上市公司"）拟向 力诺投资控股集团有限公司（以下简称"力诺投资"）、力诺集团股份有限公司 （以下简称"力诺集团"）等 38 名交易对方发行股份购买其持有的山东宏济堂 制药集团股份有限公司（以下简称"宏济堂"）99.42%股权，同时上市公司拟向 不超过 3 ...

中信建投证券股份有限公司 关于山东科源制药股份有限公司本次重组 相关主体买卖股票情况自查报告的核查意见 山东科源制药股份有限公司（以下简称"科源制药"、"上市公司"）拟向 力诺投资控股集团有限公司（以下简称"力诺投资"）、力诺集团股份有限公司（以 下简称"力诺集团"）等 38 名交易对方发行股份购买其持有的山东宏济堂制药集 团股份有限公司（以下简称"宏济堂"）99.42%股权，同时上市公司拟向不超过 35 名符合条件的特定对象发行股份募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内 容与格式准则第 26 号——上市公司重大资产重组》、深圳证券交易所《上市公司 自律监管指引第 8 号——重大资产重组》等法规、相关规范的要求，中信建投证 券股份有限公司（以下简称"中信建投证券"）作为本次交易的独立财务顾问， 对上市公司本次交易相关相关主体买卖公司股票的情况进行了核查，认为：基于 本次交易相关主体核查范围及相关机构和人员的自查情况，并在上述相关主体出 具的自查报告及承诺函均真实、准确、完整的前提下，该等主体在自查期间买卖 上市公司股票的行为不构成内幕交易行为 ...

一、本次股东大会召开的基本情况 证券代码：301281 证券简称：科源制药 公告编号：2025-032 山东科源制药股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开 第四届董事会第七次会议，审议通过了《关于提请召开 2025 年第二次临时股东 大会的议案》，公司董事会决定于 2025 年 6 月 11 日 15:00 以现场投票与网络投 票相结合的方式召开公司 2025 年第二次临时股东大会（以下简称 "本次股东大 会"），现将会议的有关情况通知如下： 会议的召集、召开符合有关法律、行政法规、部门规章、其他规范性文件及《山 东科源制药股份有限公司章程》的有关规定。 （1）现场会议召开时间：2025 年 6 月 11 日（星期三）15:00 （2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统 进行网络投票的具体时间为：2025 年 6 月 11 日 9:15—9:25，9:30—11:30，13:00 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-041 山东科源制药股份有限公司 关于召开2025年第二次临时股东大会的通知的更正公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 21 日披露了《关于召 开 2025 年第二次临时股东大会的通知》（公告编号 2025-032）。经审查，原公告中提案编码 有误，现对该公告中的内容予以补充更正，本次更正不涉及原通知的实质性变更，敬请投资者 关注。具体内容如下： 更正前： …… 二、会议审议事项 1、本次股东大会审议事项及提案编码： | 提案编码 | 提案名称 | 备注 | | --- | --- | --- | | | | 该列打勾的栏目可以投票 | | 100 | 总议案：除累积投票提案外的所有提案 | √ | | 非累积投票提案 | | | | 1.00 | 《关于公司符合发行股份购买资产并募集配套 | √ | | | 资金相关法律法规规定条件的议案》 | | | 2.00 | 《关于公司发行股份购买资产并募集配套资金 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-032 山东科源制药股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开 第四届董事会第七次会议，审议通过了《关于提请召开 2025 年第二次临时股东 大会的议案》，公司董事会决定于 2025 年 6 月 11 日 15:00 以现场投票与网络投 票相结合的方式召开公司 2025 年第二次临时股东大会（以下简称 "本次股东大 会"），现将会议的有关情况通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开经过董事会审议通过， 会议的召集、召开符合有关法律、行政法规、部门规章、其他规范性文件及《山 东科源制药股份有限公司章程》的有关规定。 4、会议召开的日期与时间 （1）现场会议召开时间：2025 年 6 月 11 日（星期三）15:00 （2 ...

Economic Overview - In 2024, Shandong's GDP reached 98,565.8 billion yuan, growing by 5.7% year-on-year, with the primary, secondary, and tertiary industries contributing 6.7%, 40.2%, and 53.1% respectively [2] - The province's listed companies are crucial for economic development, focusing on green, low-carbon, and high-quality growth while enhancing technological innovation [2] Performance of Listed Companies - Shandong's listed companies achieved a total revenue of 2.95 trillion yuan in 2024, a year-on-year increase of 4.61%, while net profit was 175.9 billion yuan, down 3.20% [4] - 78.96% of the companies reported profits, which is 5.27 percentage points higher than the national average, indicating better performance despite challenges in traditional industries [4][5] Contribution to Economic Growth - Listed companies in Shandong contributed 29.92% of the province's GDP, with an added value of 705.18 billion yuan, reflecting their significant role in regional economic growth [5] - The labor productivity of listed companies was 483,600 yuan per person, 2.78 times the national average, showcasing their efficiency [5] Innovation and Growth of SMEs - In 2024, 67 companies on the Growth Enterprise Market reported revenues of 177.98 billion yuan, up 15.13%, and net profits of 11.74 billion yuan, up 49.42%, indicating strong growth in innovative SMEs [6] - The total R&D expenditure for these companies was 6.44 billion yuan, a 8.11% increase, highlighting their commitment to innovation [6] Market Capitalization and Value Management - By the end of 2024, the market capitalization of Shandong's listed companies reached 3.63 trillion yuan, a 4.18% increase, ranking seventh nationally [8] - 125 companies conducted share buybacks, totaling 9.568 billion yuan, reflecting a strong commitment to value management [8] Characteristics of Listed Companies - Private listed companies in Shandong accounted for 62.14% of the total, achieving revenues of 838.06 billion yuan, up 4.64%, and net profits of 431.87 billion yuan, up 16.49% [9][10] - Companies with overseas business generated 842.85 billion yuan in foreign income, a year-on-year increase of 8.89%, indicating the importance of international markets [12] Mergers and Acquisitions - In 2024, 13 listed companies in Shandong participated in mergers and acquisitions, with a total transaction value of 38.75 billion yuan, a 3.58-fold increase [14][15] - The trend of state-owned enterprises merging with peers is becoming more common, enhancing market competitiveness [15] Sustainable Development and ESG - Shandong's listed companies showed a 44.34% ESG report disclosure rate, slightly above the national average, indicating a growing recognition of sustainability [16][17] - The average ESG score for Shandong's companies was 5.79, higher than the national average, with two companies scoring above 9.00 [17] Innovation and Digital Transformation - R&D expenses for Shandong's listed companies reached 84.51 billion yuan, a 3.94% increase, with a focus on enhancing innovation capabilities [18] - The digital economy's core companies reported revenues of 330.38 billion yuan, up 27.57%, demonstrating significant growth in this sector [20] Traditional Industry Transformation - Traditional industries in Shandong are undergoing digital and intelligent transformations, with companies like Shandong High-Speed adopting advanced technologies to enhance operational efficiency [23] - The integration of digital and green technologies is seen as essential for fostering new productive forces in traditional sectors [24]

Group 1 - A recent study from the University of California, San Diego, found that women with type 2 diabetes taking metformin have a 30% higher chance of living to 90 years or older compared to those using sulfonylureas [1] - Metformin is evolving from a traditional diabetes medication to a potential anti-aging treatment, with increasing evidence suggesting its role in longevity [1] - The study establishes a link between metformin monotherapy and the likelihood of living to 90 years or older, filling a research gap in this area [1] Group 2 - Key companies involved in metformin production include Koyuan Pharmaceutical, which produces metformin hydrochloride raw materials and tablets for type 2 diabetes treatment [2] - Another company, Teva Pharmaceutical, produces metformin sustained-release tablets that reduce liver glucose production and improve insulin sensitivity [2]

Core Viewpoint - The second largest shareholder of Koyuan Pharmaceutical plans to reduce its stake in the company, which has led to a significant drop in the company's stock price following the announcement [1][2]. Group 1: Shareholder Actions - Koyuan Pharmaceutical announced that its second largest shareholder, Wen Zehong, who holds 8.4 million shares (7.76% of total shares), intends to reduce his holdings by up to 3% of the total shares, equating to a maximum of 3.2487 million shares [1]. - The reduction is attributed to Wen Zehong's personal funding needs, with the shares being from his holdings prior to the company's initial public offering [1]. Group 2: Stock Performance - Following the announcement of the share reduction, Koyuan Pharmaceutical's stock price opened lower and fell by over 10% on May 26 [2]. - The company's stock had previously surged from 19.59 yuan per share on September 24, 2022, to a peak of 58.66 yuan per share by October 29, 2022, before experiencing a continuous decline [2]. Group 3: Financial Performance - Koyuan Pharmaceutical's main business involves the research, production, and sales of chemical raw materials and their formulations, covering key disease areas such as diabetes, anesthesia, cardiovascular, and mental health [2]. - In 2023, the company reported a revenue increase of 1.07% but a net profit decrease of 15.6%. For 2024, revenue is expected to grow by 3.6%, while net profit is projected to decline by 21.54%, indicating a trend of increasing revenue but decreasing profitability [2]. - The company's net profit margin has decreased from 20.61% in 2022 to 13% in 2024, highlighting significant challenges in profitability [2]. - The net cash flow from operating activities turned negative in 2024, recording -60.5158 million yuan, compared to a positive 37.031 million yuan in 2023 [2]. Group 4: M&A Activity - Koyuan Pharmaceutical is currently engaged in an acquisition transaction, planning to issue shares and pay cash to acquire 99.42% of Shandong Hongjitang Pharmaceutical Group [3]. - The transaction involves multiple related parties, including its controlling shareholder, Lino Investment, indicating that it constitutes a related party transaction [4].

Core Viewpoint - The stock price of Koyuan Pharmaceutical (301281) plummeted after the announcement that its second-largest shareholder, Wen Zehong, plans to reduce his stake by 3%, indicating potential lack of confidence in the company's future performance [1][6]. Group 1: Stock Performance - On May 26, Koyuan Pharmaceutical's stock fell by 8.03%, closing at 32.42 yuan per share, with a total market capitalization of 3.511 billion yuan [3]. - The stock opened down 5.39% and experienced a decline of over 10% during the trading session [3]. - The trading volume for the day was 317 million yuan, with a turnover rate of 14.34% [3]. Group 2: Shareholder Actions - Wen Zehong, the second-largest shareholder, holds 8.4 million shares, representing 7.76% of the total share capital [4]. - The planned reduction involves selling up to 3.2487 million shares, which is 3% of the total share capital, through both centralized bidding and block trading [3][5]. Group 3: Financial Performance - Koyuan Pharmaceutical's revenue for 2023 was approximately 448 million yuan, a year-on-year increase of 1.07%, but the net profit attributable to shareholders decreased by 15.6% to about 77 million yuan [9]. - In 2024, the company expects a further decline in net profit, projected at 60.4 million yuan, down 21.54% year-on-year, despite a revenue increase to approximately 464 million yuan [9]. - The company attributed the profit decline to increased sales costs, lower sales prices, and higher asset impairment losses [9]. Group 4: Future Plans - Koyuan Pharmaceutical is planning a restructuring, aiming to acquire 99.42% of Hongjitang's shares for approximately 3.581 billion yuan and raise up to 700 million yuan through a share issuance to specific investors [10]. - The restructuring aims to expand the company's business into traditional Chinese medicine and health products [10].